Search Results - "Mark J. Giganti"

Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America by Belaunzaran-Zamudio, Pablo F, Caro-Vega, Yanink, Giganti, Mark J, Castilho, Jessica L, Crabtree-Ramirez, Brenda E, Shepherd, Bryan E, Mejía, Fernando, Cesar, Carina, Moreira, Rodrigo C, Wolff, Marcelo, Pape, Jean W, Padgett, Denis, McGowan, Catherine C, Sierra-Madero, Juan G, Nunes, Bruno Pereira

“…Background A growing population of older adults with HIV will increase demands on HIV-related healthcare. Nearly a quarter of people receiving care for HIV in…”
Get full text

The impact of data quality and source data verification on epidemiologic inference: a practical application using HIV observational data by Giganti, Mark J, Shepherd, Bryan E, Caro-Vega, Yanink, Luz, Paula M, Rebeiro, Peter F, Maia, Marcelle, Julmiste, Gaetane, Cortes, Claudia, McGowan, Catherine C, Duda, Stephany N

“…Data audits are often evaluated soon after completion, even though the identification of systematic issues may lead to additional data quality improvements in…”
Get full text

Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia by Marseille, Elliot, Giganti, Mark J, Mwango, Albert, Chisembele-Taylor, Angela, Mulenga, Lloyd, Over, Mead, Kahn, James G, Stringer, Jeffrey S A

“…We estimated the unit costs and cost-effectiveness of a government ART program in 45 sites in Zambia supported by the Centre for Infectious Disease Research…”
Get full text

A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy by Wolff, Marcelo J, Giganti, Mark J, Cortes, Claudia P, Cahn, Pedro, Grinsztejn, Beatriz, Pape, Jean W, Padgett, Denis, Sierra-Madero, Juan, Gotuzzo, Eduardo, Duda, Stephany N, McGowan, Catherine C, Shepherd, Bryan E

“…In Latin America, the first wave of HIV-infected patients initiated highly active antiretroviral therapy (HAART) 10 or more years ago. Characterizing their…”
Get full text

Measuring coverage in MNCH: population HIV-free survival among children under two years of age in four African countries by Stringer, Jeffrey S A, Stinson, Kathryn, Tih, Pius M, Giganti, Mark J, Ekouevi, Didier K, Creek, Tracy L, Welty, Thomas K, Chi, Benjamin H, Wilfert, Catherine M, Shaffer, Nathan, Stringer, Elizabeth M, Dabis, Francois, Coetzee, David

“…Population-based evaluations of programs for prevention of mother-to-child HIV transmission (PMTCT) are scarce. We measured PMTCT service coverage, regimen…”
Get full text

Self-audits as alternatives to travel-audits for improving data quality in the Caribbean, Central and South America network for HIV epidemiology by Lotspeich, Sarah C, Giganti, Mark J, Maia, Marcelle, Vieira, Renalice, Machado, Daisy Maria, Succi, Regina Célia, Ribeiro, Sayonara, Pereira, Mario Sergio, Rodriguez, Maria Fernanda, Julmiste, Gaetane, Luque, Marco Tulio, Caro-Vega, Yanink, Mejia, Fernando, Shepherd, Bryan E, McGowan, Catherine C, Duda, Stephany N

“…Audits play a critical role in maintaining the integrity of observational cohort data. While previous work has validated the audit process, sending trained…”
Get full text

Multiple-Imputation Variance Estimation in Studies With Missing or Misclassified Inclusion Criteria by Giganti, Mark J, Shepherd, Bryan E

“…Abstract In observational studies using routinely collected data, a variable with a high level of missingness or misclassification may determine whether an…”
Get full text

Health outcomes among HIV‐positive Latinos initiating antiretroviral therapy in North America versus Central and South America by Cesar, Carina, Koethe, John R, Giganti, Mark J, Rebeiro, Peter, Althoff, Keri N, Napravnik, Sonia, Mayor, Angel, Grinsztejn, Beatriz, Wolff, Marcelo, Padgett, Denis, Sierra‐Madero, Juan, Gotuzzo, Eduardo, Sterling, Timothy R, Willig, James, Levison, Julie, Kitahata, Mari, Rodriguez‐Barradas, Maria C, Moore, Richard D, McGowan, Catherine, Shepherd, Bryan E, Cahn, Pedro

“…Introduction Latinos living with HIV in the Americas share a common ethnic and cultural heritage. In North America, Latinos have a relatively high rate of new…”
Get full text

Response to Drs de Grooth and Parienti by Giganti, Mark J, Chew, Kara W, Eron, Joseph J, Smith, Davey M, Currier, Judith S, Hughes, Michael D

Get full text

Causes of stillbirth, neonatal death and early childhood death in rural Zambia by verbal autopsy assessments by Turnbull, Eleanor, Lembalemba, Mwila K., Brad Guffey, M., Bolton‐Moore, Carolyn, Mubiana‐Mbewe, Mwangelwa, Chintu, Namwinga, Giganti, Mark J., Nalubamba‐Phiri, Mutinta, Stringer, Elizabeth M., Stringer, Jeffrey S. A., Chi, Benjamin H.

“…Summary Objectives  To describe specific causes of the high rates of stillbirth, neonatal death and early child childhood death in Zambia. Methods  We…”
Get full text

Plasma biomarker factors associated with neurodevelopmental outcomes in children with perinatal HIV infection and controlled viremia by Kapetanovic, Suad, Giganti, Mark J., Abzug, Mark J., Lindsey, Jane C., Sirois, Patricia A., Montepiedra, Grace, Canniff, Jennifer, Agwu, Allison, Boivin, Michael J., Weinberg, Adriana

“…We examined relationships between plasma biomarkers and neurodevelopment in children from sub-Saharan Africa with perinatal HIV (PHIV) with controlled viremia…”
Get full text

Coordination of inflammatory responses in children with perinatally-acquired HIV infection by Weinberg, Adriana, Giganti, Mark J., Sirois, Patricia A., Montepiedra, Grace, Canniff, Jennifer, Agwu, Allison, Boivin, Michael J., Kapetanovic, Suad, Abzug, Mark J.

“…We investigated dynamics of inflammatory biomarkers in children with perinatally acquired HIV (PHIV) who started antiretrovirals at age less than 3 years and…”
Get full text

Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery by Shivakoti, Rupak, Giganti, Mark J, Lederman, Michael M, Ketchum, Rachel, Brummel, Sean, Moisi, Daniela, Dadabhai, Sufia, Moodley, Dhayendre, Violari, Avy, Chinula, Lameck, Owor, Maxensia, Gupta, Amita, Currier, Judith S, Taha, Taha E, Fowler, Mary Glenn

“…HIV treatment regimen during pregnancy was associated with preterm delivery (PTD) in the PROMISE 1077 BF trial. Systemic inflammation among pregnant women with…”
Get full text

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 by Evering, Teresa H, Chew, Kara W, Giganti, Mark J, Moser, Carlee, Pinilla, Mauricio, Wohl, David Alain, Currier, Judith S, Eron, Joseph J, Javan, Arzhang Cyrus, Bender Ignacio, Rachel, Margolis, David, Zhu, Qing, Ma, Ji, Zhong, Lijie, Yan, Li, D'Andrea Nores, Ulises, Hoover, Keila, Mocherla, Bharat, Choudhary, Manish C, Deo, Rinki, Ritz, Justin, Fischer, William A, Fletcher, Courtney V, Li, Jonathan Z, Hughes, Michael D, Smith, Davey, Daar, Eric S

“…Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal…”
Get full text

Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 by Choudhary, Manish C, Deo, Rinki, Evering, Teresa H, Chew, Kara W, Giganti, Mark J, Moser, Carlee, Ritz, Justin, Regan, James, Flynn, James P, Crain, Charles R, Wohl, David Alain, Currier, Judith S, Eron, Joseph J, Margolis, David, Zhu, Qing, Zhon, Lijie, Ya, Li, Greninger, Alexander L, Hughes, Michael D, Smith, Davey, Daar, Eric S, Li, Jonathan Z

“…Abstract Background Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…”
Get full text

Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials by Moser, Carlee B, Chew, Kara W, Giganti, Mark J, Li, Jonathan Z, Aga, Evgenia, Ritz, Justin, Greninger, Alexander L, Javan, Arzhang Cyrus, Bender Ignacio, Rachel, Daar, Eric S, Wohl, David A, Currier, Judith S, Eron, Joseph J, Smith, Davey M, Hughes, Michael D

“…Abstract Most clinical trials evaluating coronavirus disease 2019 (COVID-19) therapeutics include assessments of antiviral activity. In recently completed…”
Get full text

Variant-Specific Viral Kinetics in Acute COVID-19 by Ribeiro, Ruy M, Choudhary, Manish C, Deo, Rinki, Giganti, Mark J, Moser, Carlee, Ritz, Justin, Greninger, Alexander L, Regan, James, Flynn, James P, Wohl, David A, Currier, Judith S, Eron, Joseph J, Hughes, Michael D, Smith, Davey M, Chew, Kara W, Daar, Eric S, Perelson, Alan S, Li, Jonathan Z

“…Abstract Understanding variant-specific differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral kinetics may explain differences in…”
Get full text

Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial by Chew, Kara W, Taiwo, Babafemi O, Moser, Carlee, Daar, Eric S, Wohl, David Alain, Ritz, Justin, Javan, Arzhang Cyrus, Li, Jonathan Z, Fischer, William, Greninger, Alexander L, Bausch, Christoph, Luke, Thomas, Call, Robert, Neytman, Gene, Giganti, Mark J, Fletcher, Courtney V, Hughes, Michael D, Eron, Joseph J, Currier, Judith S, Smith, Davey M, Chew, Kara, Smith, David (Davey), Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Javan, Arzhang Cyrus, Hughes, Michael, Moser, Carlee, Giganti, Mark, Ritz, Justin, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Beck, Justine, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Fischer, William, Evering, Teresa, Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jagannathan, Prasanna, Jilg, Nikolaus, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Singh, Upinder, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Kosmyna, Jan, Gapara, Morgan, Shahkolahi, Akbar

“…Abstract Background We evaluated the fully human polyclonal antibody product SAB-185 in a phase 3 trial for COVID-19. Methods Nonhospitalized high-risk adults…”
Get full text

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial by Jilg, Nikolaus, Chew, Kara W, Giganti, Mark J, Daar, Eric S, Wohl, David A, Javan, Arzhang Cyrus, Kantor, Amy, Moser, Carlee, Coombs, Robert W, Neytman, Gene, Hoover, Keila, Jana, Atasi, Hart, Phil A, Greninger, Alexander L, Szurgot, Bob, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Smith, Davey M, Li, Jonathan Z

“…Abstract Background Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vitro. We studied the safety and efficacy of…”
Get full text

Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19 by Taiwo, Babafemi O, Chew, Kara W, Moser, Carlee, Wohl, David Alain, Daar, Eric S, Li, Jonathan Z, Greninger, Alexander L, Bausch, Christoph, Luke, Thomas, Hoover, Keila, Neytman, Gene, Giganti, Mark J, Olefsky, Maxine, Javan, Arzhang Cyrus, Fletcher, Courtney V, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Smith, Davey M

“…In this phase 2 evaluation of SAB-185 in the ACTIV-2/ACTG A5401 platform trial of investigational agents for outpatient COVID-19 treatment, this…”
Get full text